Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Auranofin is lethal against feline Tritrichomonas foetus in vitro but ineffective in cats with naturally occurring infection.

Veterinary parasitology·2024
Same author

Pharmacists' Knowledge of Veterinary Pharmacotherapy and the Impact of an Educational Intervention.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians·2021
Same author

Baseline knowledge of potential pet toxins: a survey of pharmacists.

Pharmacy practice·2018
Same author

Assessment of in vitro release of carboplatin from six carrier media.

American journal of veterinary research·2016
Same author

To compound or not to compound: a veterinary transdermal discussion.

International journal of pharmaceutical compounding·2015
Same author

Twice-daily dosing of RDZ no longer recommended for treatment of intestinal Tritrichomonas foetus infection.

Journal of feline medicine and surgery·2013
Same journal

Compounding and Stability Study of Dipyridamole and Clopidogrel Pediatric Oral Suspensions.

International journal of pharmaceutical compounding·2026
Same journal

Nanoemulsion Reformulation of Nitrosylcobalamin (NO-Cbl) Enhances Solubility, Stability, and Anti-Tumor Potency.

International journal of pharmaceutical compounding·2026
Same journal

Chemical and Microbiological Stability Supporting Extended BUDs in Pentravan® Based Transdermal Preparations.

International journal of pharmaceutical compounding·2026
Same journal

Stability Evaluation of Compounded Benzocaine, Lidocaine, and Tetracaine in VersaPro™ Cream Base.

International journal of pharmaceutical compounding·2026
Same journal

Formulation and In-Vitro Characterization of Gastroretentive Effervescent Floating Tablets of Meloxicam.

International journal of pharmaceutical compounding·2026
Same journal

Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities.

International journal of pharmaceutical compounding·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Veterinary compounding for myasthenia gravis.

Gigi S Davidson1

  • 1College of Veterinary Medicine, Veterinary Teaching Hospital Pharmacy, Raleigh, North Carolina, North Carolina State University.

International Journal of Pharmaceutical Compounding
|August 24, 2013
PubMed
Summary
This summary is machine-generated.

Veterinary myasthenia gravis patients face treatment challenges due to drug shortages. Compounding pharmacists can provide essential compounded medications, ensuring continued care and a good quality of life for affected animals.

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

Related Experiment Videos

Last Updated: May 8, 2026

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

Area of Science:

  • Veterinary Neurology
  • Pharmacology
  • Animal Health

Background:

  • Myasthenia gravis is a neuromuscular disorder common in veterinary medicine.
  • Successful management relies on accurate diagnosis and treatment.
  • Commercial drug availability is frequently impacted by manufacturer shortages.

Purpose of the Study:

  • To highlight the challenges posed by drug shortages in veterinary myasthenia gravis management.
  • To emphasize the critical role of compounding pharmacists in mitigating these shortages.
  • To ensure continuity of care and maintain patient quality of life.

Main Methods:

  • Review of myasthenia gravis treatment protocols in veterinary medicine.
  • Analysis of the impact of drug unavailability on patient care.
  • Identification of compounding pharmacy services as a solution.

Main Results:

  • Drug shortages disrupt the standard diagnosis and treatment of myasthenia gravis in animals.
  • Compounded medications offer a viable alternative when commercial drugs are unavailable.
  • Compounding ensures consistent therapeutic options for veterinary patients.

Conclusions:

  • Compounding pharmacists are vital in managing veterinary myasthenia gravis during drug shortages.
  • Access to compounded drugs is crucial for maintaining remission and a normal life for affected animals.
  • Collaboration between veterinarians and compounding pharmacists ensures optimal patient outcomes.